Jyoti Acharya
Research Subjects
Jyoti Acharya has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Sheetal Middha
Department of Medicine, S.P. Medical College, Bikaner, Rajasthan, India
9 shared publications - Dhanpat Kumar Kochar
Rajasthan University of Health Sciences, Jaipur, Rajasthan, India
8 shared publications - Sanjay Kumar Kochar
Department of Medicine, S.P. Medical College, Bikaner, Rajasthan, India
8 shared publications - Amit Kumar Subudhi
King Abdullah University of Science and Technology
7 shared publications - Pon Arunachalam Boopathi
Department of Biological Sciences, Birla Institute of Technology and Science (BITS), Pilani, Rajasthan, India
6 shared publications - Ashis Das
Department of Biological Sciences, Birla Institute of Technology and Science (BITS), Pilani, Rajasthan, India
5 shared publications
Latest Publications
- 1 December 2016
- Published by Elsevier in Acta Tropica
- Vol. 164, 438-447
Design, construction and validation of a Plasmodium vivax microarray for the transcriptome profiling of clinical isolates
- 1 December 2016
- Published by Elsevier in Acta Tropica
- Vol. 164, 438-447
Design, construction and validation of a Plasmodium vivax microarray for the transcriptome profiling of clinical isolates
- Open Access
- 1 September 2016
- Published by Elsevier in Genomics Data
- Vol. 9, 118-125
A cross strain Plasmodium falciparum microarray optimized for the transcriptome analysis of Plasmodium falciparum patient derived isolates
- 1 September 2016
- Published by Elsevier in Genomics Data
- Vol. 9, 118-125
Open AccessA cross strain Plasmodium falciparum microarray optimized for the transcriptome analysis of Plasmodium falciparum patient derived isolates
- 1 May 2015
- Published by Elsevier in Molecular and Biochemical Parasitology
- Vol. 201 (1) , 31-46
Plasmodium falciparum complicated malaria: Modulation and connectivity between exportome and variant surface antigen gene families
- 1 May 2015
- Published by Elsevier in Molecular and Biochemical Parasitology
- Vol. 201 (1) , 31-46
Plasmodium falciparum complicated malaria: Modulation and connectivity between exportome and variant surface antigen gene families
- Open Access
- 1 December 2014
- Published by Elsevier in Genomics Data
- Vol. 2, 393-395
An in vivo transcriptome data set of natural antisense transcripts from Plasmodium falciparum clinical isolates
- 1 December 2014
- Published by Elsevier in Genomics Data
- Vol. 2, 393-395
Open AccessAn in vivo transcriptome data set of natural antisense transcripts from Plasmodium falciparum clinical isolates
- Open Access
- 1 December 2014
- Published by Elsevier in Genomics Data
- Vol. 2, 199-201
Dataset of natural antisense transcripts in P. vivax clinical isolates derived using custom designed strand-specific microarray
- 1 December 2014
- Published by Elsevier in Genomics Data
- Vol. 2, 199-201
Open AccessDataset of natural antisense transcripts in P. vivax clinical isolates derived using custom designed strand-specific microarray
- 27 September 2010
- Published by Taylor & Francis in Platelets
- Vol. 21 (8) , 623-627
Thrombocytopenia inPlasmodium falciparum,Plasmodium vivaxand mixed infection malaria: A study from Bikaner (Northwestern India)
The occurrence, relation and magnitude of thrombocytopenia in different species of malaria are not clearly defined. This study included 1,064 patients admitted with malaria to study thrombocytopenia (platelet count Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) mono infection and mixed infection (Pf + Pv). The species diagnosis was done by peripheral blood film (PBF) and rapid diagnostic test (RDT). Validation by polymerase chain reaction (PCR) was done only in patients with severe thrombocytopenia (platelet count Pf, 460 (43.23%) Pv and 79 (7.42%) mixed malaria (Pf + Pv). Thrombocytopenia was observed in 24.6% (262/1064) patients. The risk was greatest in the mixed infections in comparison to monoinfection individually (43.04% [34/79]; mixed vs Pv monoinfection: Odds Ratio [OR] = 1.675 [95% Confidence Interval (CI) 1.029–2.726], p < 0.0366; mixed vs Pf monoinfection: OR=3.911 [95% CI 2.367–6.463], p < 0.0001). Pv monoinfection (31.09% [143/460]) had greater risk compared to Pf monoinfection (16.19% [85/525]; OR = 2.335 [95% CI 1.722–3.167], p < 0.0001). The occurrence of severe thrombocytopenia was also higher in Pv monoinfection (18.18% [26/143]) in comparison to either Pf monoinfection (10.59% [9/85], OR = 1.877 (95% CI 0.834–4.223)) or mixed infection (11.76% [4/34]; OR = 1.667 (95% CI 0.540–5.142) but this association was statistically not significant. Six patients (3 Pv, 2 Pf and 1 mixed) developed severe epistaxis requiring platelet transfusion. There was no relation between parasite density and platelet count as many patients with severe thrombocytopenia had parasite density similar to patients without thrombocytopenia. We found that the association of thrombocytopenia was statistically more significant with P. vivax monoinfection as compared to P. falciparum.
- 27 September 2010
- Published by Taylor & Francis in Platelets
- Vol. 21 (8) , 623-627
Thrombocytopenia inPlasmodium falciparum,Plasmodium vivaxand mixed infection malaria: A study from Bikaner (Northwestern India)
The occurrence, relation and magnitude of thrombocytopenia in different species of malaria are not clearly defined. This study included 1,064 patients admitted with malaria to study thrombocytopenia (platelet count Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) mono infection and mixed infection (Pf + Pv). The species diagnosis was done by peripheral blood film (PBF) and rapid diagnostic test (RDT). Validation by polymerase chain reaction (PCR) was done only in patients with severe thrombocytopenia (platelet count Pf, 460 (43.23%) Pv and 79 (7.42%) mixed malaria (Pf + Pv). Thrombocytopenia was observed in 24.6% (262/1064) patients. The risk was greatest in the mixed infections in comparison to monoinfection individually (43.04% [34/79]; mixed vs Pv monoinfection: Odds Ratio [OR] = 1.675 [95% Confidence Interval (CI) 1.029–2.726], p < 0.0366; mixed vs Pf monoinfection: OR=3.911 [95% CI 2.367–6.463], p < 0.0001). Pv monoinfection (31.09% [143/460]) had greater risk compared to Pf monoinfection (16.19% [85/525]; OR = 2.335 [95% CI 1.722–3.167], p < 0.0001). The occurrence of severe thrombocytopenia was also higher in Pv monoinfection (18.18% [26/143]) in comparison to either Pf monoinfection (10.59% [9/85], OR = 1.877 (95% CI 0.834–4.223)) or mixed infection (11.76% [4/34]; OR = 1.667 (95% CI 0.540–5.142) but this association was statistically not significant. Six patients (3 Pv, 2 Pf and 1 mixed) developed severe epistaxis requiring platelet transfusion. There was no relation between parasite density and platelet count as many patients with severe thrombocytopenia had parasite density similar to patients without thrombocytopenia. We found that the association of thrombocytopenia was statistically more significant with P. vivax monoinfection as compared to P. falciparum.
- 1 September 2010
- Vol. 47 (3) , 140-4
Comparison of quinine and rabeprazole with quinine monotherapy in the treatment of uncomplicated falciparum malaria.
This study was conducted to assess the effect of combination treatment of quinine and rabeprazole in the treatment of uncomplicated Plasmodium falciparum malaria. The study included 50 patients of uncomplicated P. falciparum malaria. Group 1 (25 patients) received quinine and placebo (Q+P) while Group 2 (25 patients) received quinine and rabeprazole (Q+R). Diagnosis was confirmed by peripheral blood film (PBF) and rapid diagnostic test (RDT). Temperature was recorded every 6 h. All patients were followed-up on Days 7, 14, 21, 28 for detailed clinical and parasitological examination. A total of 20 patients in each group completed the treatment and followed-up for 28 days. While two patients in Group 1 (Q+P) and one patient in Group 2 (Q+R) were lost in follow-up; and seven (Q+P = 4, Q+R =3) patients were withdrawn from the study. Fever clearance time (FCT) of the two groups was also almost similar (Group 1 : 2 = 52.8 : 51.3 h). No statistically significant difference was observed in early treatment failure (ETF) either of the groups. None of the patients in both the groups showed late clinical failure (LCF) or late parasitological failure (LPF). However, there was a significant difference in the parasite clearance rates of the two groups (p<0.05). The study results suggest that addition of rabeprazole to quinine regimen resulted in an increase in the parasite elimination rate, which may be helpful in reducing the duration of treatment and increasing patient compliance.
- 1 September 2010
- Vol. 47 (3) , 140-4
Comparison of quinine and rabeprazole with quinine monotherapy in the treatment of uncomplicated falciparum malaria.
This study was conducted to assess the effect of combination treatment of quinine and rabeprazole in the treatment of uncomplicated Plasmodium falciparum malaria. The study included 50 patients of uncomplicated P. falciparum malaria. Group 1 (25 patients) received quinine and placebo (Q+P) while Group 2 (25 patients) received quinine and rabeprazole (Q+R). Diagnosis was confirmed by peripheral blood film (PBF) and rapid diagnostic test (RDT). Temperature was recorded every 6 h. All patients were followed-up on Days 7, 14, 21, 28 for detailed clinical and parasitological examination. A total of 20 patients in each group completed the treatment and followed-up for 28 days. While two patients in Group 1 (Q+P) and one patient in Group 2 (Q+R) were lost in follow-up; and seven (Q+P = 4, Q+R =3) patients were withdrawn from the study. Fever clearance time (FCT) of the two groups was also almost similar (Group 1 : 2 = 52.8 : 51.3 h). No statistically significant difference was observed in early treatment failure (ETF) either of the groups. None of the patients in both the groups showed late clinical failure (LCF) or late parasitological failure (LPF). However, there was a significant difference in the parasite clearance rates of the two groups (p<0.05). The study results suggest that addition of rabeprazole to quinine regimen resulted in an increase in the parasite elimination rate, which may be helpful in reducing the duration of treatment and increasing patient compliance.
- 1 December 2009
- Vol. 46 (4) , 307-9
Acute attack of AIP (acute intermittent porphyria) with severe vivax malaria associated with convulsions: a case report.
- 1 December 2009
- Vol. 46 (4) , 307-9
Acute attack of AIP (acute intermittent porphyria) with severe vivax malaria associated with convulsions: a case report.